Here’s the reading behind the claims on these pages. I’ve kept a note beside each source about what it can tell us. A paper can be useful without settling the whole decision. These seven records answer different questions, so I don’t add them up like votes.
Researchers tested rat cells, rats and pigs. Ipamorelin triggered growth-hormone release without the same rise in stress hormones seen with some older peptides. That comparison explains the word selective. It wasn’t a test of better sleep or recovery in people.
Healthy men received infusions into a vein. Researchers measured Ipamorelin in the blood and a short-lived rise in growth hormone. This tells us about that route and response. It doesn’t provide a schedule for injections under the skin or show a wellness benefit.
The trial asked whether Ipamorelin helped gut function recover after bowel surgery. Its main measure was time to the first tolerated meal; that comparison with placebo wasn’t statistically significant. That hospital result doesn’t settle every possible use.
Ipamorelin increased body fat in this mouse study. That complicates the claim that raising growth hormone necessarily means losing fat. It doesn’t predict weight gain in a person.
FDA’s page, current as of April 22, 2026, lists Ipamorelin acetate as nominated but withdrawn for 503A and in Category 2 for 503B. Withdrawal isn’t clearance. Its safety concerns include possible immune reactions with some injection routes, peptide impurities and gaps in information about other injection routes.
FDA’s October 2024 meeting review
This document separates the free base from the acetate salt and examines the evidence. It discusses serious events after bowel surgery without settling whether Ipamorelin caused them. It covers safety questions a study abstract can leave out.
The record describes a larger, completed bowel-surgery study. As of October 1, 2026, the record had no posted results. I don’t count completion as success or failure. Without the results, there’s no outcome here to quote.
When a finding sounds convincing, I look again at who was studied and how the compound was given. Those details help show whether the paper answers the question in front of me. A familiar ingredient name isn’t enough to connect two different settings.
The research page puts the main results together. I leave unknown outcomes unknown, including when the record looks official.